冻干注射剂市场（2026—2031）
冻干注射剂市场规模预计由2026年的4663.5亿美元增至2031年的9102亿美元，预测期复合年增长率为14.31%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
冻干注射剂市场规模预计由2026年的4663.5亿美元增至2031年的9102亿美元，预测期复合年增长率为14.31%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 14.31% | 机构预测 |
| 市场规模 | 2026 | USD 466.35 billion | 机构预测 |
| 市场规模 | 2031 | USD 910.2 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| distribution_channel | hospital pharmacies | 2025 | 51.530% |
| drug_class | anti-infective drugs | 2025 | 41.540% |
| end_user | hospitals | 2025 | 43.540% |
| geography | North America | 2025 | 44.280% |
| indication | metabolic conditions | 2025 | 25.650% |
| packaging | vials | 2025 | 48.540% |
| type_of_delivery | prefilled diluent syringes | 2025 | 42.540% |
关键结论
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 51.53%。
- drug_class 维度中，anti-infective drugs 在 2025 年的公开份额为 41.54%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 43.54%。
- geography 维度中，North America 在 2025 年的公开份额为 44.28%。
- indication 维度中，metabolic conditions 在 2025 年的公开份额为 25.65%。
- packaging 维度中，vials 在 2025 年的公开份额为 48.54%。
主要参与者
- Catalent, Inc.
- Vetter Pharma-Fertigung GmbH & Co. KG
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Baxter International Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Stable, Long Shelf-Life Injectable Demand | +2.800% | Global, with acute gains in North America and Europe | Short term (≤ 2 years) |
| Biologics, Vaccines, and Specialty Injectable Expansion | +3.500% | North America, EU, APAC core | Medium term (2-4 years) |
| Chronic-Disease Injectable Treatment Volumes | +2.000% | Global, APAC and MEA fastest scaling | Medium term (2-4 years) |
| Contract Development and Manufacturing Capacity Growth | +1.800% | North America, EU, India, China | Medium term (2-4 years) |
| Freeze-Dried mRNA and Lipid Nanoparticle Development | +1.500% | North America and EU with spill-over to APAC | Long term (≥ 4 years) |
| Lower Cold-Chain Dependence in Remote Distribution | +1.200% | APAC, MEA, South America | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High Lyophilization Capital and Operating Costs | -1.500% | Global, most acute in APAC emerging markets and South America | Short term (≤ 2 years) |
| Complex Process Validation and Sterile Quality Control | -1.000% | Global, EMA and FDA jurisdictions in particular | Medium term (2-4 years) |
| Container-Closure and Reconstitution-Device Compatibility Risks | -0.800% | North America, EU regulatory-intensive markets | Medium term (2-4 years) |
| Limited Commercial-Scale Capacity for Emerging Biopharma | -0.700% | Global, concentrated in North America and EU pipeline | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for lyophilized injectable products?
Demand is supported by stable storage needs for biologics, vaccines, oncology medicines, and other specialty injectables.
What is the projected growth rate for lyophilized injectables?
The sector is forecast to grow at a CAGR of 14.31% from 2026 to 2031, reaching USD 910.20 billion by 2031.
Which drug class has the largest share of lyophilized injectable demand?
Anti-Infective Drugs held the largest drug-class share at 41.54% in 2025.
Why are cartridges gaining importance for lyophilized therapies?
Cartridges support dual-chamber and self-administration systems, and they are forecast to grow at a 16.34% CAGR through 2031.
Which end users account for most lyophilized injectable demand?
Hospitals held 43.54% of demand in 2025, while Specialty Clinics are forecast to expand at a 17.22% CAGR through 2031.
Which region is growing fastest for lyophilized injectable products?
Asia-Pacific is forecast to grow at a 15.65% CAGR through 2031, supported by expanding biologics manufacturing and treatment demand.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence